Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Biomica Completes Enrollment for Phase I Trial of Microbiome-Based Immuno-Oncology Drug
Details : BMC128, a rationally designed microbial consortium selected using functional microbiome analysis, is in Phase 1 clinical trials for treating NSCLC, melanoma, and renal cell carcinoma.
Product Name : BMC128
Product Type : Microorganism
Upfront Cash : Inapplicable
January 17, 2024
Biomica Announces Closing of $20 Million Financing Round led by Shanghai Healthcare Capital
Details : The proceeds will be used to complete Biomica's current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial and to scale up and complete GMP production of BMC333 in preparation for a phase 1 clinical trial for the treatment of IBD.
Product Name : BMC128
Product Type : Microorganism
Upfront Cash : Undisclosed
April 27, 2023
Details : BMC128 is a rationally designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform powered by Evogene's MicroBoost AI platform.
Product Name : BMC128
Product Type : Microorganism
Upfront Cash : Inapplicable
July 26, 2022
Lead Product(s) : BMC128,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomica to Present at the ASCO 2022 Annual Meeting
Details : Biomica’s abstract entitled “A rationally designed live bacterial consortium for the potentiation of immune checkpoint therapy in solid tumors”, was selected for a poster and presentation session at the conference which showcase the potential of BM...
Product Name : BMC128
Product Type : Microorganism
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : BMC128,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomica to Present at the Microbiome Connect Europe 2022
Details : BMC128 is a rationally designed microbial consortium identified and selected through a detailed functional microbiome analysis using PRISM, a proprietary high-resolution microbiome analysis platform.
Product Name : BMC128
Product Type : Microorganism
Upfront Cash : Inapplicable
May 07, 2022
Lead Product(s) : BMC128,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Rambam Health Care Campus
Deal Size : Undisclosed
Deal Type : Agreement
Details : The clinical trial agreement (CTA) is signed for initiating a first in-human proof-of-concept (POC) for BMC128, Biomica's drug candidate which is rationally-designed LBP consortium comprised of four unique bacterial strains, natural inhabitants of the hu...
Product Name : BMC128
Product Type : Microorganism
Upfront Cash : Undisclosed
October 27, 2021
Lead Product(s) : BMC128,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Rambam Health Care Campus
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : BMC128,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMC128 is advancing to the GMP production stage following the successful completion of the initial R&D stage of drug product development and manufacturing, conducted by Biose Industrie (Aurillac, France).
Product Name : BMC128
Product Type : Microorganism
Upfront Cash : Inapplicable
October 13, 2020
Lead Product(s) : BMC128,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BMC128,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program
Details : Biomica’s current results demonstrate that treatment with BMC128 prior to and in combination with the administration of ICI, significantly reduced tumor volume and increased animal survival compared to ICI therapy alone.
Product Name : BMC128
Product Type : Microorganism
Upfront Cash : Inapplicable
August 09, 2020
Lead Product(s) : BMC128,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable